Has lapatinib been reimbursed by medical insurance?

The original drug Lapatinib has been withdrawn from the market in mainland China and is therefore not included in the national medical insurance reimbursement catalog. Although the drug was sold under the trade name "Tykerb" in the early days in China and was used to treat patients with HER2-positive advanced breast cancer, it was eventually withdrawn from the Chinese market due to market demand, competition from similar drugs and pricing factors. With the successive launch of new generation HER2-targeted drugs such as pertuzumab and neratinib, lapatinib has been gradually replaced in clinical use in China.

However, lapatinib remains on sale in the international market, and both the original drug and generic drugs are on the market. Taking the original version produced in Turkey as an example, the common specification is 0.25g × 70 tablets, and each box sells for about 2,000 yuan; while Indian generic drugs are priced at about 600 yuan due to lower production costs. Whether it is the original research or the generic version, its drug ingredients, dosage standards and efficacy mechanisms are basically the same. For patients who need to purchase drugs across borders, they need to ensure that the channels are legal, the packaging is compliant, and they are used under the guidance of professional doctors to prevent risks.

From a medical insurance perspective, since lapatinib is not sold in the domestic market, it cannot be included in the medical insurance catalog and does not have a basis for medical insurance payment. However, it is worth noting that special drug assistance programs or charitable drug projects in some areas may still provide certain support to patients who have used this drug. Internationally, lapatinib is still regarded as a backup treatment option for HER2-positive breast cancer, especially in the treatment phase after resistance to other drugs.

In the future, with the improvement of the global generic drug quality consistency evaluation system, if lapatinib re-enters the Chinese market as a low-priced generic version, it may have the opportunity to be included in medical insurance. Generally speaking, although domestic patients are currently unable to purchase lapatinib through medical insurance reimbursement, obtaining original drugs or generic drugs through regular overseas pharmacy channels can still be an alternative.

Reference materials:https://medlineplus.gov/druginfo/meds/a607055.html